SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine
Biosciences, will be presenting at Credit Suisse's 24th
Annual Healthcare Conference in Scottsdale, AZ.
The live presentation takes place on Wednesday, November 11 at 10:30am MT (9:30am
PT/12:30pm ET). The
presentation will be webcast and may be accessed on the Company's
website at http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial
rights to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-credit-suisses-24th-annual-healthcare-conference-300172599.html
SOURCE Neurocrine Biosciences, Inc.